Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

7.110 -0.140 (-1.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 610,198
Open 7.210
Bid (Size) 6.800 (1)
Ask (Size) 7.320 (1)
Prev. Close 7.250
Today's Range 7.020 - 7.280
52wk Range 3.465 - 9.820
Shares Outstanding 50,547,986
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings for Marinus Pharma
 
Via Benzinga
Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire

Performance

YTD
+67.29%
+67.29%
1 Month
-22.08%
-22.08%
3 Month
+3.04%
+3.04%
6 Month
+48.13%
+48.13%
1 Year
+46.60%
+46.60%

More News

Read More
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharma: Q1 Earnings Insights
Via Benzinga
Where Marinus Pharma Stands With Analysts
Via Benzinga
RBC Capital Maintains Outperform Rating for Marinus Pharma: Here's What You Need To Know
Via Benzinga
6 Analysts Have This to Say About Marinus Pharma
Via Benzinga
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Earnings Outlook For Marinus Pharmaceuticals
Via Benzinga
Noting Strong Progress On Marinus Pharma's Lead Drug Ganaxolone, Analyst Initiates With 300% Upside
Via Benzinga
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors
From Marinus Pharmaceuticals
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
Via Benzinga
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Marinus Pharmaceuticals
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.